EuPFI 2020 VIRTUAL CONFERENCE

Thank you for attending the day one of our first ever EuPFI virtual conference 2020! We hope that you had a successful meeting so far, enjoyed the presentations/Q&A sessions and made some productive connections. With everything new, there’s a learning curve. We appreciate your patience while we work diligently to provide you with the best possible experience with this new virtual platform.

We look forward to seeing you for the second day! Best wishes

.

Conference Dates

September 9 to 10^th,2020

Welcome to EuPFI 12th Annual Conference (Virtual)

Thank you for attending the day one of our first ever EuPFI virtual conference 2020! We hope that you had a successful meeting so far, enjoyed the presentations/Q&A sessions and made some productive connections. With everything new, there’s a learning curve. We appreciate your patience while we work diligently to provide you with the best possible experience with this new virtual platform.

Conference information

Key Dates

Live conference from 13:00 CET on Wednesday, 9th September to Thursday, 10th September, using Vfairs
Exhibitions open on Wednesday, 9th September to Thursday, 10th September,
On-Demand Meeting Content: Available to full registrants until 10th October. One-day meeting registrants will only have access to that day.

Meeting Time Zone

The meeting times will be displayed in Coordinated Universal Time (UTC). Check the time in your own time zone here.

Find an overview of what the virtual platform looks like below. You can also have a look at this short training video to familiarise yourself with the virtual platform.

Virtual Lobby

Through virtual lobby access auditorium, exhibit hall, the poster hall, the networking lounge, or the information desk. Just select the room you want to enter

Live and pre-recorded sessions

Enter the auditorium to join us for the opening ceremony plenary keynote sessions, focus sessions and soap box sessions including Q&A sessions post each talk. All presentations (prerecorded presentations with audio) will be available for online viewing on demand. Each live Q&A session provides options to interact with the presenter. Selected times for live interactions will apply, but questions and answers will be recorded and remain accessible one month after the conference.Watch it on demand at a later stage.

e-Poster Hall

Click on e-poster hall to view the posters and listen to 2-minute video description from the authors. All presentations (prerecorded presentations with audio) will be available for online viewing on demand. Use the live chat room to interact with the presenter. Selected times for live interactions may apply, e-posters with audio presentation will remain accessible one month after the conference. Watch it on demand at a later stage.

Exhbit Hall

Enter exhibition hall to visit exhibition booths showing content (video, pdf, etc) made available by the exhibitors. Interact with representatives of the exhibiting organization by ono-to-one chat, voice call or video call. you can book a time with exhibitor to visit and interact with the exhibitor at the time convenient to you during the entire day of the conference.

Networking lounge

Networking lounge will create the experience of live in person meeting. Make most of the live chats in structured and open sessions organised for you in the relaxed atmosphere of networking lounge. Don’t miss regular visits to the Networking Lounge to engage with others in chat rooms… Choose for one-to-one interaction by chat or for a public chat with all delegates or with selected groups (e.g. age appropriate formulation group, excipients group, taste masking and taste assessment group, devices group etc.) Want to book an appointment to meet your colleagaues? Go to the delegates area and book a time to interact with delegates which you can find by search based on their profile (name, affialition, country, scientific area of interest..etc).

Programme

For EuPFI 2020 Programme Click here

Sign up to our mailing list here and we will send you an email when the programme is online and keep visiting the website for conference updates in the meanwhile.

EuPFI 2020 Call for Abstracts

• Abstract Topics
• Eligibility
• Responsibilities of the Presenting Author
• Author's Consent and Waiver of Claims
• General Guidelines
• Preferred Presentation Format
• Requesting Special Consideration
• Abstract Review and Selection Process
• Acceptance/Rejection Notification
• Abstract Withdrawal
• Publication on EuPFI website
• Late-Breaking Abstracts
• Abstract Submission Policies
• How to Submit an Abstract
• Preparing an Abstract for Submission
• PCCA Awards
• EuPFI Young Scientist Travel Award
• Abstract Template
• Contact Information

Abstract Topics

1. Age appropriateness of formulations
2. Administration devices
3. Biopharmaceutics
4. Excipients
5. Developing paediatric formulations for low resource settings
6. Taste Assessment and Taste Masking

back to top

---

Eligibility

To submit an abstract, the following criteria must be met:

• Research and/or studies must fit into one of the EuPFI abstract topics listed above
• Data already published by 1st Sept either online or in print, data presented at a national or international meeting will generally not be eligible for consideration. We encourage the authors to request special consideration (see section below) if the abstract is a minor extension of published work.

back to top

---

Responsibilities of the Presenting Author

• The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the “Presenter Information” section of the online abstract submission system.
• The presenting author must be one of the co-authors listed on the submitted abstract.
• The presenting author is responsible for the following:
  • Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
  • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by EuPFI.
  • Obtaining all of the conflict-of-interest disclosure and copyright transfer information from co-authors.
  • Forwarding all correspondence to all co-authors, including EuPFI submission guidelines and reviewers comments.

back to top

---

Author's Consent and Waiver of Claims

• Each abstract author agrees and certifies that he or she:
  • has read all of the rules and agrees to be bound by them,
  • is responsible for submission of the abstract in accordance with the rules, and
  • waives any and all claims against EuPFI and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.

back to top

---

General Guidelines

• The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.
• No revisions can be made after the abstract submission deadline, unless requested by the reviewers.
• Abstracts generally may not be withdrawn once submitted. If you prefer that your abstract be withdrawn if not accepted for any presentation at the EuPFI conference, you must indicate so during online submission.
• The presentation at the EuPFI conference must reflect the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation at the conference must match the submitted abstract, although updates on results may be added.
• Abstracts should be written in clear and concise English, so that reviewers are able to focus solely on the scientific merits of the submission. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling prior to submission.

back to top

---

Preferred Presentation Format

During submission, submitters must choose the formats in which they would be willing to present/publish their abstract. These choices must be made at the time of submission and cannot be changed after the review committee has reached its decision.

• Authors should select whether they prefer oral or poster presentation. Abstracts noted with a preference for poster presentation will NOT be considered for oral presentation, regardless of score.
• Second, in the event that an abstract is not chosen for oral presentation, it can still be chosen for poster presentation. Authors who state a preference for oral presentation must decide whether they would accept poster presentation. Authors may either present a poster or request that the abstract be immediately withdrawn. (Please note that declining to have your abstract considered for poster presentation does not improve its chances of being accepted as an oral presentation. This option should be selected primarily by authors who would not be willing to present a poster.)
• Finally, in the event the abstract is NOT selected for oral or poster presentation, it must be noted that their abstract will NOT be published on the EuPFI website.

back to top

---

Requesting Special Consideration

• Special consideration may be requested by explaining the special circumstances in the text box provided during the online abstract submission process. We encourage authors to request special consideration if the abstract is a minor extension of previously published work or if the author has a reason to believe that the data will be published, either online or in print, or presented in any form prior to the conference. The information provided will be carefully evaluated by the reviewers.
• Failure of authors to request special consideration for an abstract, including content that has been published or presented at a major national or international meeting (‘major’ is defined as 1,000 or more attendees) or in a press release published before the EuPFI conference, will result in exclusion from the program.

back to top

---

Abstract Review and Selection Process

• After the submission deadline, all completed and eligible abstracts will be made available to the reviewing committee for blinded review and scoring, and final decisions will be made by the Program Committee.
• Abstracts will be evaluated and scored solely on their scientific merits.
• Incomplete abstracts will not be reviewed.
• The same study must not be submitted as multiple abstracts. Abstracts that are simply different versions of a single study will be rejected.
• Abstracts will be peer reviewed according to the topics. Authors must indicate during online submission the appropriate review category (one only). Please select the topic that is most closely associated with your abstract.
• All accepted abstracts will be considered eligible for poster presentation even if it is selected for oral soapbox session. If the author, whose abstract is selected for oral, does not wish to present the poster, the author must inform the committee by sending the email to admin@eupfi.org
  • Oral (soapbox) Sessions are formal 10 minutes oral presentations followed by a 3 min Q&A.
  • Poster Sessions allow the viewing of a poster illustration of the abstract. Authors are expected to post and remove posters at designated times and to be at their posters to answer questions during the time designated for poster presentations. The author’s attendance during poster presentation time will be monitored.

back to top

---

Acceptance/Rejection Notification

• Notification regarding acceptance or rejection of abstracts will be sent to the presenting author by 30th July 2020 by email; consequently, an accurate email address is critical. If your abstract is accepted, the e-mail will specify whether it is accepted as oral, or poster presentation. If you have not received an email notification by July 20, 2020, contact admin@eupfi.org. Rejection notifications will also be sent at that time.
• To ensure that you are able to receive email correspondence from EuPFI, please make sure that you use your email as the username while registering to the abstracts submission system.  If after completing your submission you don't receive a confirmation email from the abstract system within three working days, you must contact EuPFI at admin@eupfi.org
• The decision of the EuPFI conference committee regarding acceptance and presentation of abstracts is final.

s back to top

---

Abstract Withdrawal

• Once an abstract is accepted, a written request to withdraw must be submitted no later than Sept 1st, 2020 to admin@eupfi.org. If the first author decides to withdraw the abstract for any reason. Abstract withdrawal requests received after the deadline will be considered on a case-by-case basis.
• EuPFI reserves the right to withdraw abstracts that are not as per the submission guidelines, such as those that have been previously published or presented, have been deemed scientifically unsound, or have been found to include inaccurate data, etc.
• If you indicated at submission that you wish to withdraw your abstract if it is not accepted for either oral or poster presentation, your abstract will be automatically withdrawn, and you will be notified; you do not need to request withdrawal.

back to top

---

Publication on the EuPFI website

• All abstracts accepted for presentation (oral, or poster) at the EuPFI 2020 conference will be published on the EuPFI website
• If an author does not want the abstract published, he/she must indicate that during submission.
• EuPFI reserves the right not to publish abstracts that do not fit into any of the topics, abstracts that inappropriately promote commercial interests, abstracts that are judged unethical, poorly written, or scientifically unsound, or abstracts considered inappropriate for publication for other reasons as determined by the Program Committee.

back to top

---

Late-Breaking Abstracts

Recognising that the results of some top-quality research may not be available by the general abstract submission deadline, the EuPFI Program Committee offers an option for late-breaking abstracts. Late-breaking abstracts will undergo regular peer-review evaluation.  The accepted abstracts will be published. Late-breaking abstracts will not be considered for oral presentations but only for poster presentation.

back to top

---

Abstract Submission Policies

Author Responsibility Regarding Conflict of Interest Disclosure

• The presenting author is responsible for obtaining disclosure information from all co-authors.
• All authors and co-authors are required to provide any relevant information concerning personal or professional circumstances and relationships that might reasonably be expected to affect the author’s view on the presentation.
• This includes relationships with pharmaceutical companies, biomedical device manufacturers, or other companies whose products or services are related to the subject matter of the presentation topic. If no relevant relationships exist, this must be stated as well.

back to top

---

How to Submit an Abstract

Abstracts must be submitted online through the official online abstract submission site

We will acknowledge the receipts of abstracts in 5 working days. If you don't get the acknowledgement email please inform us at admin@eupfi.org Or s.salunke@ucl.ac.uk.

Any technical questions regarding the submission process should be directed to admin@eupfi.org

please click here to view the STEP-by-STEP guide to abstract submission

back to top

---

Preparing an Abstract for Submission

please click here to view the abstract template

Dos and Don'ts

• Your name, degree, institution, address, phone number, and e-mail address must be provided. As the corresponding author, you will receive all future correspondence from EuPFI.
• Please underline the name of the author who will present the abstract. Ideally, the corresponding author should be the first author (presenter) of the abstract, unless otherwise noted during submission.

Co-Authors

• Names of co-authors and institutions must be provided. Changes will not be made to the spelling of authors’ names after the submission deadline; please proof your co-authors’ names carefully.

Abstract Title

• The abstract title should be brief and clearly indicate the nature of the abstract.
• The abstract title must be in sentence case and bold.
• Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as pH or NaCl.
• Do not put a period at the end of the title.

Use of Product Names

• Non-proprietary (generic/scientific) names should be used and should be lowercase.
• If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalised. EuPFI reserves the right to replace proprietary names with generic names to adhere to this policy.

Abbreviations

• Use standard abbreviations. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract.

Abstract Body, Tables, and Figures

• Abstracts accepted for the EuPFI 2020 will be published in a EuPFI special . Abstracts will be typeset from the text submitted by the author without copyediting changes. It is the responsibility of the author to proofread the abstract carefully.
• There is no limit on word or characters of the abstract. However the entire body of the abstract, including title, authors, text and tables, must not exceed one A4 size page.
• The abstract should be structured (i.e., divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) .
• Do not use bold type or underline formatting for the body of the abstract. Italic type is acceptable. Only the Title and Authors must be bold.
• Text may be in multiple paragraphs. Do not indent the first line of paragraphs.
• Special Greek and mathematical symbols are available in a character map within the submission system.
• Use numerals to indicate numbers, except when beginning sentences.
• Simple tables and graphs may be included.
• Any references should be noted as citations within the text and not as footnotes at the end.

Selection of Abstract Review Category

• Be sure to select from the topics that best describes your abstract. Note that the abstract will be reviewed in the topic you selected.

back to top

---

Abstract Template

please click here to view the abstract template

back to top

---

PCCA Awards

This year again we have 3 Poster Awards and 1 Oral presentation Award sponsored by PCCA. The overall purpose with the award is to encourage students and early career researchers to share experiences and results with others through quality poster presentations.
Number Offered: Four awards of Euros 250 each for the best 3 poster presentations and 1 oral presentation made by a student/early career researchers at the EuPFI Annual Conference.
Application Closing Date: Eligible poster/Oral author who wish to be considered for the “Best Student Poster/Oral Award” have to indicate their interest during the submission of the abstract by July 15th 2020. The participants need to raise the interest at the time of submission of abstract. Click on button ‘would like to participate in PCCA award’ during the submission of abstract.
How to be considered for an Abstract Achievement Award:

• Eligible poster/oral author who wish to be considered for the “Best Student Poster/Oral Award” have to indicate their interest during the submission of the abstract by 15th July
• Submit the pdf copy of poster by 20th Aug 2020 to admin@eupfi.org, if you have registered the interest while submission. Please note that if you do not submit the pdf copy of your poster by deadline, your poster won't be considered for the award.
• All eligible posters will be on display throughout the event and lead authors will be required to be present to answer questions about their posters at set times during the event
• The best posters should make a significant contribution towards improving identified issues and challenges associated with development of paediatric formulation, to ultimately raise awareness and consider ways towards better medications and clinically relevant dosage forms for children. Award Criteria
  • The applicant must be the presenting, and thus first named, author of the abstract.
  • The abstract must be the only one submitted by the applicant for that award. Only one award per student.
  • The abstract must not be entered for consideration for any other Annual Conference awards.
  • The work presented must have been completed as part of a first degree, a taught Masters degree or a postgraduate qualification (PhD). Work must be presented within 12-months of completion of the degree.
  • The awards will be given for excellence, reflected in the content, presentation and defence quality of the poster.
  • The Awards Panel's decision is final in all cases. The panel is composed of PCCA and EuPFI  representatives.
  • After the meeting, “electronic” versions of the winning posters will be posted on EuPFI and PCCA websites.
  • About the SponsorProfessional Compounding Centers of America (PCCA) is a multinational company dedicated to the advancement of pharmaceutical compounding through its over 4,000 members worldwide. For more than 30 years, PCCA has been a leading resource for the highest quality raw materials; innovative bases, equipment and devices; compounding pharmacy software; specialised consultancy services and accredited education and training. PCCA’s mission is to strengthen the role, position and skills of member pharmacists so they can meet the unique healthcare needs of patients through compounded medications.http://www.pccarx.com/what-is-compounding/specialty-compounding/pediatric-compounding

Abstract Achievement Award Notifications:

Abstract Achievement Award recipients will be notified and will receive an award on day two of the conference.

back to top

---

EuPFI Young Scientist Award

This year again we would like to announce EuPFI Young Scientist Award, supporting development of younger scientists in the paediatric formulation research. This award will provide free registration for students, young and early-career scientists to attend and present a soap box talk or poster at the EuPFI 2020 virtual conference.

Number Offered: 1 award is available to enable individuals to attend the EuPFI 2020 Virtual Conference and present the research. Awards are made on the basis of scientific merit and financial need.

Eligibility: Applicants must be currently:
• Under the age of 35 years of age at the time of application
• A full time student, post-doc OR within the first five (5) years of a professional career
• Submitted a data-driven abstract that meets EuPFI' requirements
• First author of an abstract accepted for selected for presentation at EuPFI 2020
• The author MUST register and present the poster or oral presentation at the conference

How to apply: The travel award will open for applications on 30th April 2020. The applicant will be required to complete the application form. CLICK HERE TO COMPLETE AND SUBMIT THE APPLICATION FORM . The application includes sections where the applicant needs to specify details on how the grant will be spent and and how the applicant will benefit from this opportunity The completed application must be accompanied by
• A short biography for publication on the EuPFI website (100 words or less)
• Your current curriculum vita or resume including your permanent address (PDF or DOC).
Application Evaluation Criteria: Applicants must submit an abstract in accordance with the EuPFI Call for Abstracts to be eligible for a travelship. Please note that travelships are contingent on the acceptance of the abstract for presentation by the EuPFI Screening Committee. The abstract will be evaluated according to the following key criteria:
• Is the conclusion of the study data-driven?
• Will viewers find this study novel or exciting?
• Does this study advance its field?
• Does the author's selected strategy for evaluating the hypothesis suit the project?
Check the box that indicates to which theme your abstract relates and if you wish to participate to travel awards when you submit the abstract through submission system.

Application Deadline: The deadline for submitting applications for travel award is closed . All application material must be received by the application close date for consideration. Late applications will not be considered. Travel awards cannot be used for meetings already attended. Posters will be displayed at the EuPFI Virtual conference in September 2020 All poster presenters must be registered by July 15th. Any winner that is not registered by July 15th will have both the registration and the poster withdrawn.
back to top

---

Contact Information

Send related correspondence and questions regarding abstract submissions or notifications to admin@eupfi.org
back to top

Registration Guidelines

All participants are kindly recommended to register via Online Registration Form on APV website. Please fax this document to APV Headquarters: 0049 6131 9769-69 or send it via email to apv@apv-mainz.de. Please read the instructions on the APV website carefully.

Upon submitting the Registration Form, You will receive a confirmation by e-mail of your registration with the invoice.

All participants are kindly requested to register in advance by completing and submitting the Registration Form with the appropriate fees.

Registration fees

Please note unpaid pre-registration will not be considered as a valid registration unless fully paid and confirmed. Pre-registration summary therefore cannot be taken as a valid registration confirmation. Please make sure to pay your registration fee within the time frame for early or regular registration.

Students have to submit a copy of their student ID to the Conference email/contact address or fax number. Please note that if we do not receive this certification within 7 days after your data submission your registration will not be considered as valid. 

Delegate registration fee includes

• Admission to scientific sessions, exhibition and poster area
• Conference materials

Insurance

The registration fees do not include insurance of participants against accidents, sickness, cancellation, theft, property damage or loss. Participants are advised to take out adequate personal insurance.

Confirmation

Upon receipt of the correct registration fee (clear of bank charges), each participant will receive a confirmation of registration. Please bring this confirmation to the Registration desk at the conference venue as proof of your registration. Confirmation will be sent upon receipt of payment.

Payment

All fees for the Conference registration should be paid in EUR (€), free of all bank charges.

Payment options

• credit card payment (Visa, Eurocard/Mastercard)
   
• by bank transfer
  

Cancellation / Refund Policy

We would like to point out that participation can be cancelled free of charge within two weeks of registration via the web.

Publication in the list of participants

In case you wish not to include your name and email address in the list of participants please send email to the Conference secretariat.

Responsibility

The participant acknowledges that he/she has no right to lodge damage claims against the organisers should the holding of the Conference be hindered or prevented by unexpected political or economic events or generally by force majeure, or should the non-appearance of speakers or other reasons necessitate programme changes. With registration, the participant accepts this proviso.

Exhibition and Sponsorship

 
We are glad to tailor a sponsor package (starting from 990 EUR) according to your wishes.

For general information, Click here

As an exhibitor you will be also invited to attend the sessions and networking sessions in networking lounge. At the conference center the poster presentations will again be integrated in the exhibition, ensuring that participants are around the exhibition stands as much as possible. You will be able to design your booth as per your needs. upload images and presentative and interact with participants via live chat. Price for a exhibition booths is 990 EUR.

For details regarding sponsorship and exhibition opportunities, please contact

Valentina Marinkova

Phone: ++49 6131 9769-90

E-mail: marinkova@apv-mainz.de

We look forward to seeing you virtually on 9-10th Sept 2020!

Contacts

11^th Conference of the European Paediatric Formulation Initiative

APV
International Association for Pharmaceutical Technology
Kurfürstenstraße 59, 55118 Mainz/Germany

 

Tel.: +49 6131 9769-0
Fax: +49 6131 9769-69
Website: www.apv-mainz.de
E-mail: apv@apv-mainz.de

 

 

Poster Presentations

Novel direct measurement technique for investigating kinetics of dispersion of adult tablets for pediatric compounding
Carsten Timpe, Pharm R&D NCE, F. Hoffmann-La Roche Ltd., Basel CH-4070, Switzerland

Aspirin Tablets Dispersion Guidance: Impact of Human Factors on Manipulation and Dosing Accuracy
AA. Lahiq, School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham B152TT

Current practice in the conduct of acceptability/palatability/swallowability trials: A review of methodology associated with trials registered on the EU clinical trials portfolio
E. Cooper, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK

Identification of formulation variables that affect the mouthfeel of ODTs: a review of the literature
Abdullah Asiri, School of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK

Characterization of chloroquine ion-exchange resinates in the solid-state and in vitro taste masking evaluation for a future paediatric formulation
Thiago Frances Guimarães, Laboratório de Farmacotécnica Experimental, Instituto de Tecnologia em Fármacos, FIOCRUZ.Rua Sizenando Nabuco 100 - Manguinhos. Rio deJaneiro – RJ, Brazil. E-mail: thiago.guimaraes@far.fiocruz.br

Quantification of fluid volumes and distribution in the paediatric colon via Magnetic Resonance Imaging (MRI)
Jan Goelen, School of Pharmacy, Institute of Clinical Science, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

3D Printing with HPMCAS for Personalized Medicines
Joana Ângelo, Tobias Eggers, Andreas Sauer,Shin-Etsu Tylose GmbH & Co. KG, Rheingaustraße 190-196, 65203 Wiesbaden, Germany, joana.angelo@setylose.com

Development of Age Appropriate oral formuation as Spheronised Granules to Treat Childhood Tuberculosis
Alyaa Alsalhi, University of Birmingham ,AXA1317@student.bham.ac.uk

Scaling up fluidised bed coating of sustained release microparticles at high spray rate using the MicroCoatTM technology
F. Liu, Fluid Pharma Ltd., Windsor House, Cornwall Road, Harrogate, HG1 2PW, UK

Paediatric formula/on research capabili/esin Europe:the European Paediatric Transla/onal Research Infrastructure EPTRI roadmap
Donato Bonifazi;Valeria Pignataro;Mariangela Lupo,Giovanni Migliaccio,Elisa Alessandrini,Nunzio Denora,Adriana Ceci,Catherine Tuleu on behalf of European Paediatric TranslaPonal Research Infrastructure (EPTRI) project

What do children think about tablets manufactured using different 3D printing methods?
Xiaoyan Xu, Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK

Investigating the Impact of Age on Oral Montelukast Pharmacokinetics Using in vitro dissolution and PBPK Modeling?
Mariana Guimarães, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK

Evaluation of mucoadhesive buccal films using porcine mucosa and synthetic mucosa-mimetic material
A. Göbel, Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University, 40225 Düsseldorf, Germany

GE-APPROPRIATE FORMULATION FOR CAPTOPRIL TRANSDERMAL DELIVERY IN PAEDIATRIC PATIENTS
Noelia Nieto González,Department of Chemistry and Pharmacy, University of Sassari, via Muroni 23a, 07100-Sassari, Italy

Dynamic compaction analysis as a QbD tool for paediatric orodispersible minitablet preparation
Sonia Iurian, epartment of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy

Impact of different tooling systems on mini-tableting
Ard Lura Jörg Breitkreutz,epa Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University, 40225 Düsseldorf, Germany+492118114891  ard.lura@hhu.de

Rapid Dissolving Capsules for the Administration of Gastro-Resistant Prednisolone Microparticles for Paediatric Patients
K. Patel, Department of Clinical and Pharmaceutical Sciences, University of Hertfordshire, UK

Microparticle-filled straw for the delivery of sustained release metformin for the treatment of Type II Diabetes Mellitus in Paediatric Populations
K. Patel, Department of Clinical and Pharmaceutical Sciences, University of Hertfordshire, UK

DEVELOPMENT OF ANTITUBERCULOSIS ORAL SOLUTION USING 2-HP-β-CD FOR PAEDIATRIC TREATMENT
Amor R. Cáceres‐Pérez, Programa Doctorado en Ciencias Médicas y Farmacéuticas, Desarrollo y Calidad de Vida. Universidad de La Laguna, 38200, Tenerife, Spain

STABILITY EVALUATION OF A NEW CHILD-FRIENDLY DISPERSIBLE TABLET FOR TREATING TUBERCULOSIS
Magariños-Triviño María, Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias. Universidad de La Laguna. 38203. Tenerife

Design and optimization of a dispersible tablet for treating tuberculosis in paediatrics
Eduardo Díaz-Torres,Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna, 38200 La Laguna (Tenerife), Spain

Novel Mini-Tablet Dispenser Supports Flexible Oral Dosing
Bjørn Knud Andersen,Director Front-End Innovation, Phillips-Medisize

Accuracy of dispensing of an oral syringe vs. scoop for dosing multiparticulate formulations: Naïve user study
Hofmanová Justyna Katarzyna,School of Pharmacy, University of Birmingham, Birmingham, UK

A novel oral syringe for multiparticulate formulations: The end-user experience
Hofmanová1 Justyna Katarzyna,School of Pharmacy, University of Birmingham, Birmingham, UK

QUININE IMPREGNATED TASTE STRIPS CAN BE USED TO ASSESS BITTERNESS PERCEPTION IN PRIMARY SCHOOL CHILDREN
Sejal R Ranmal,UCL School of Pharmacy, 29-39 Brunswick Square, London, WC1N 1AX, UK

Evaluation of the medicine acceptability in paediatric patients treated in tertiary care hospital in India
Manjusha Sajith, Poona college of pharmacy, Bharati Vidyapeeth (Deemed) university, Pune, Maharashtra, India

IFUs and Children in Administrative Device Human Factors Studies
Gabi Bitting,Jennifer DeLuca,Sophia Levin,Wala Siddig,Gretchen Vogt,

Age-Appropriate Formulations at Any Cost? A Canadian Case Example
Émilie Kate Landry, The Rosalind & Morris Goodman Family Pediatric Formulations Centre of the CHU Sainte-Justine

Tramadol chocolate oral formulation:pharmacokinetics and tolerability
O.Yoo, School of Allied Health, Okhee.yoo@research.uwa.edu.au

Prior Administration of Chocolate Improves the Palatability of Bitter Medications - The Choc-with-Med Study
S. Truong, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia

Storage stability of chocolate-based CDS formulations of midazolam and tramadol
L.R.Benington, Pharmacy, School of Allied Health, University of Western Australia, Australia

Optimising the process of blending for carvedilol to develop a pediatric specific formulation
Dilawar Khan, Aston Pharmacy School, School of Life & Health Sciences, Aston University, Birmingham, B4 7ET

A pilot study on the use of devices for oral and respiratory paediatric medicines: An Indian perspective
Varsha Pokharkar, 1Poona College Of Pharmacy, Bharati Vidyapeeth (Deemed University), Pune, India

Knowledge, attitude and practice of healthcare professionals (HCPs) towards prescribing and administrating different dosage forms for children in Pakistan
Ramees Nanitalwala, University College London School of Pharmacy,, London WC1N 1AX, UK

Knowledge, attitude and practices among parents regarding different dosage forms and administrating medicines to children: a pilot cross-sectional study from Karachi
Ramees Nanitalwala, University College London School of Pharmacy,, London WC1N 1AX, UK

Na Salts as Taste-modifying Excipients for Children; BATA Findings
Danielle Andrews

EXCIPIENTS IN PARENTERAL FORMULATIONS USED IN PAEDIATRICS AND NEONATAL PATIENTS: A SYSTEMATIC REVIEW
FIONA O’BRIEN, SCHOOL OF PHARMACY AND BIOMOLECULAR SCIENCES, RCSI UNIVERSITY OF MEDICINE AND HEALTH SCIENCES, DUBLIN 2, IRELAND

“Use of Liquids and/or Soft Foods as Vehicles for Drug Administration´: are the vehicles listed in the current FDA draft guidance of global relevance?
Franci Naumann, University of Greifswald, Department of Pharmacy, C_DAT, Felix-Hausdorff Straße 3, 17489 Greifswald, Germany

Plenary Presentations

Development of a child appropriate formulation of 13-Cis Retinoic Acid (isotretinoin) for the treatment of high risk neuroblastoma (My-CRA)
Hussain Mulla, Senior Clinical Pharmacist and Researcher in Clinical PK/PD, University Hospitals of Leicester, Head of Clinical Development and Regulatory, Nova Laboratories Limited, UK

Rising to Challenge of Formulating Medicines for Children in India
Arvind K. Bansal, Professor & Head Department of Pharmaceutics National Institute of Pharmaceutical Education & Research (NIPER), S.A.S. Nagar, Punjab INDIA

Remdesivir: Challenges of Paediatric Development for SARS CoV-2 Infection During a Pandemic
Cheryl Pikora, MD, PhD Senior Director, Gilead Sciences Inc, US

The emerging role of non-governmental organizations (NGOs) in global drug development: CHAI and the Global Accelerator for Pediatric Formulations (GAP-f) as collaborators to advance pediatric medicines
Linda L. Lewis, Clinical and Regulatory Affairs Product Development and Regulatory Affairs Team Clinton Health Access Initiative, US

Focus Session Presentations

It’s a kind of MAGIC: MRI of gastrointestinal transit in paediatrics
Prof. Luca Marciani, University of Nottingham, Uk

Regulatory Update Oral Syringes & Enteral Tubes
Gary Inwards, MHRA, UK and Abigail Moran, MHRA UK

Facial Recognition to Assess Palatability in Pediatric Patients: Pilot Studies
Gregory L. Kearns, Professor of Medical Education and Pediatrics Texas Christian University and UNTHSC School of Medicine Sr. Consultant, Nuventra Corporation, US

Risk Assessment of excipients in paediatric medicines in the development process
Dr Simon Bryson Founder & CEO, Proveca, UK

Soap Box Presentations

Quinine impregnated taste strips can be used to assess bitterness perception in primary school children
Sejal R Ranmal, UCL School of Pharmacy, London, UK

Accuracy of dispensing with an oral syringe vs. scoop for dosing multiparticulate formulations: Naïve user study
Justyna Katarzyna Hofmanová, University of Birmingham, UK

What do children think about tablets manufactured by different 3D printing technologies?
Xiaoyan Xu, UCL School of Pharmacy, London, UK

Characterization of chloroquine ionexchange resinatesin the solid-state and in vitro taste masking evaluation for a future paediatric formulation
Thiago Frances Guimarães;Laboratório de Farmacotécnica Experimental, Instituto de Tecnologia em Fármacos, FIOCRUZ. Rua Sizenando Nabuco 100 - Manguinhos. Rio de Janeiro – RJ, Brazil

Feasibility of amoxicillin suppositories: Storage stability and rectal bioavailability
Trusha J Purohit, School of Pharmacy, University of Auckland, New Zealand

Investigating the Impact of Age on Oral Montelukast Pharmacokinetics Using in vitro dissolution and PBPK Modeling?
Mariana Guimarães, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK